Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Liwanli Innovation Co's Revenue for the
three
months ended in Jun. 2026 was NT$203.4 Mil. Liwanli Innovation Co's average Accounts Receivable for the
three
months ended in Jun. 2026 was NT$36.2 Mil.
Hence, Liwanli Innovation Co's Receivables Turnover for the
three
months ended in Jun. 2026 was 5.62.
Liwanli Innovation Co (TPE:3054) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Liwanli Innovation Co Receivables Turnover Related Terms
Liwanli Innovation Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Liwanli Innovation Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Liwanli Innovation Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liwanli Innovation Co Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liwanli Innovation Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Liwanli Innovation Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liwanli Innovation Co (TPE:3054) has a Receivables Turnover of 5.62 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Liwanli Innovation Co and its competitors. According to the industry distribution chart, Liwanli Innovation Co ranks #50 out of 951 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Liwanli Innovation Co's Receivables Turnover too high?
Liwanli Innovation Co's current Receivables Turnover is 5.62. The Drug Manufacturers industry median Receivables Turnover is 5.06. Liwanli Innovation Co's value of 5.62 is 11.1% above this industry median. Based on the distribution chart, Liwanli Innovation Co ranks #50 out of 951 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Liwanli Innovation Co has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liwanli Innovation Co's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Liwanli Innovation Co ranks #50 out of 951 companies for Receivables Turnover. This places Liwanli Innovation Co in the top 5% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.06. Liwanli Innovation Co's value of 5.62 is 11.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.06, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liwanli Innovation Co's current Receivables Turnover of 5.62 is 11.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Liwanli Innovation Co and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liwanli Innovation Co's current Receivables Turnover is 5.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liwanli Innovation Co stock overvalued right now?
Based on GuruFocus' analysis, Liwanli Innovation Co (TPE:3054) is currently considered Possible Value Trap. The stock's GF Value™ is NT$118.43, compared to a current price of NT$48.45 — trading 59.1% below its estimated fair value. The current Receivables Turnover is 5.62 and 11.1% above the Drug Manufacturers industry median of 5.06. Liwanli Innovation Co's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Liwanli Innovation Co (TPE:3054), the current Receivables Turnover is 5.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liwanli Innovation Co (TPE:3054) Overvalued in 2026?
Based on GuruFocus' analysis, Liwanli Innovation Co stock appears to be undervalued.
The current stock price of NT$48.45 is trading 59.1% below its estimated GF Value™ of NT$118.43.
GuruFocus considers Liwanli Innovation Co to be Possible Value Trap.
Key valuation signals for TPE:3054:
Receivables Turnover: 5.62
GF Value™: NT$118.43 vs. price of NT$48.45 (59.1% below fair value)
Industry Position: 11.1% above the Drug Manufacturers median (#50 of 951)
No single metric tells the full story. See the TPE:3054 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liwanli Innovation Co Ltd is engaged in the manufacture, wholesale, and retail of electronic materials and the sales of biotech products like drug nutrient products. The reportable segments of the company are distinguished by products; the electronic department is mainly engaged in the sale and after-sales service of computer peripherals, memory and other related products; and the biotechnology department is mainly engaged in the sales of biotechnology products. Maximum revenue is generated from its Electronics department. Geographically, it generates a majority of its revenue from Taiwan, followed by other regions.
58GF Score
Get the complete analysis for TPE:3054
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3054 has been successfully added to your 
